Business Wire

InEight’s Innovations Enable Unmatched Construction Visibility

26.4.2023 16:00:00 EEST | Business Wire | Press release

Share

InEight Inc., a global leader in construction capital project management software, has announced new innovations that further realize its strategy of connecting 16 essential project controls business processes on a single, integrated platform. The new capabilities provide visibility across all construction project phases with live, “self-service” dashboards spanning scope, cost and schedule, providing the data foundation for AI to learn from past projects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230424005994/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

InEight Innovations Bigger Picture (Photo: Business Wire)

A comprehensive construction management platform, instilled with extensive construction industry expertise, is increasingly viewed as a superior alternative to multiple point solutions loosely strung together into a web of technologies that are difficult to maintain. By connecting end-to-end business processes from estimating to budgeting, from contract management to change management, and from document control to turn-over, owners, contractors and engineers can deliver smart capital projects that swiftly react to changes, with unprecedented collaboration and visibility across stakeholders.

The new innovations include a significant expansion of InEight Explore – live digital dashboards that provide full-spectrum visibility into project progress, costs and schedules, and changes and risks across entire projects and portfolios. Because the InEight dashboards are powered by embedded Microsoft Power BI, teams can easily define their own project-specific KPIs, metrics and dashboards, with no database or programming knowledge required. This unique, self-service approach to dashboards and project analytics is a key ingredient in the elevated visibility and collaboration enabled through the InEight platform.

This window into current project information also extends to completed projects, providing new opportunities to benchmark and validate project plans using historical data. Indeed, InEight’s connected data approach lays the foundation for construction organizations to create an immensely valuable knowledge library that can be used to “train” AI models to augment human intelligence. InEight can already use AI to create new project schedules and make suggestions, with future uses of AI planned for numerous workflows cutting across scope, cost, and schedule.

Brad Barth, Chief Product Officer at InEight, said: “We’re seeing greater pressure on capital project budgets and timelines, and that’s leading to an increasing need for more accurate, risk adjusted project plans, and more efficient performance. InEight is heavily invested in solving these challenges, with a connected project controls platform that removes friction from workflows, and helps all stakeholders see the bigger picture to drive more predictable project outcomes.”

About InEight

InEight provides field-tested project management software for the owners, contractors, engineers and designers who are building the world around us. Over 575,000 users and more than 850 customers worldwide rely on InEight for real-time insights that help manage risk and keep projects on schedule and under budget across the entire life cycle.

From pre-planning to design, from estimating to scheduling, and from field execution to turnover, InEight has powered more than $1 trillion in projects globally across infrastructure, public sector, energy and power, oil, gas and chemical, mining, and commercial. For more information, follow InEight on LinkedIn or visit InEight.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

press@ineight.com /
emily.sakamoto@aspectusgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye